Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
P/E ratio for Talis Biomedical Corporation (TLIS)
P/E ratio as of 2023: -0.22
According to Talis Biomedical Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.22. At the end of 2022 the company had a P/E ratio of -0.11.
P/E ratio history for Talis Biomedical Corporation from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.22 |
| 2022 | -0.11 |
| 2021 | -0.48 |
| 2020 | -1.33 |
| 2019 | -2.28 |
| 2018 | -2.94 |